Considerations for the safe prescribing and use of COX-2-specific inhibitors

Medical Journal of Australia

Volumn 176, Issue 7, 2002, Pages 328-331

  Barraclough, David R ^a   Bertouch, James V ^a   Brooks, Peter ^a   Brown, Mark A ^a   Cleland, Leslie G ^a   Clemens, Laurie E ^a   Crowley, Steven J ^a   Day, Richard O ^a   DeJager, Julien P ^a   Edmonds, John P ^a   Fletcher, Peter J ^a   Franks, Gary R ^a   Harris, David C ^a   Horowitz, John D ^a   Johnston, Michael D ^a   Kerr, Stephen J ^a   Littlejohn, Geoff O ^a   MacDonald, Graham J ^a   McColl, Geoff J ^a   Sambrook, Phillip N ^a   Shakib, Sepehr ^a   Verso, Murray W ^a   Yeomans, Neville D ^a   more..

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LITHIUM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONAMIDE; WARFARIN;

ARTHRITIS; ASTHMA; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DUCTUS ARTERIOSUS OBLITERATION; ENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LITHIUM BLOOD LEVEL; LIVER CIRRHOSIS; PEPTIC ULCER; PREGNANCY; PRESCRIPTION; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; STEADY STATE; THROMBOEMBOLISM; UPPER GASTROINTESTINAL TRACT;

EID: 0036531728     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2002.tb04434.x     Document Type: Review

References (17)

1. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
3. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis
4. Comparison of the effect of rofecoxib, ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis
5. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
6. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
7. Effects of celecoxib and naproxen on renal function in the elderly
8. Cyclooxygenase-2 specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive patients
9. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
10. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet
11. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
12. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional risk factors
13. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma
14. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects
15. Increased international normalised ratio in a patient taking warfarin and celecoxib
16. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin